Sam Brusco, Associate Editor05.01.24
Radformation, a developer of automation solutions for cancer care, has acquired privately-held Limbus AI, a provider of automated contouring software for radiation therapy.
Regina, Saskatchewan-based Limbus AI specializes in creation of artificial intelligence (AI)-driven automatic contouring algorithms performed on customers’ existing clinical workstations in the security of their local network. These software solutions help clinicians create more accurate treatment plans more quickly.
The acquisition unites two strong clinical treatment planning forces. Radformation has eight products used in over 1,600 clinics in 28 countries, and Limbus touts significant impact on 500,000 patients across 500 centers across the world.
The merger aims to combine the strengths of each company’s platform. The duo plans to integrate the best features of each of their systems to offer an advanced, AI-driven contouring solution.
Beyond improving contouring, the effort hopes to spark more innovation and lead to new developments and improvements in radiation therapy.
“Our mission has always been to improve the radiation therapy process, focusing on efficiency, quality, and safety in patient care,” said Kurt Sysock, CEO of Radformation. “With Limbus' innovative technology and expertise now part of our team, we are even more equipped to advance the frontier of innovative software solutions in radiation therapy.”
“We share a similar vision to bring innovative software to patient care,” added Karl Otto, CEO of Limbus AI. “Both companies have very talented and hardworking teams that, when combined, will be able to achieve great things together.”
Regina, Saskatchewan-based Limbus AI specializes in creation of artificial intelligence (AI)-driven automatic contouring algorithms performed on customers’ existing clinical workstations in the security of their local network. These software solutions help clinicians create more accurate treatment plans more quickly.
The acquisition unites two strong clinical treatment planning forces. Radformation has eight products used in over 1,600 clinics in 28 countries, and Limbus touts significant impact on 500,000 patients across 500 centers across the world.
The merger aims to combine the strengths of each company’s platform. The duo plans to integrate the best features of each of their systems to offer an advanced, AI-driven contouring solution.
Beyond improving contouring, the effort hopes to spark more innovation and lead to new developments and improvements in radiation therapy.
“Our mission has always been to improve the radiation therapy process, focusing on efficiency, quality, and safety in patient care,” said Kurt Sysock, CEO of Radformation. “With Limbus' innovative technology and expertise now part of our team, we are even more equipped to advance the frontier of innovative software solutions in radiation therapy.”
“We share a similar vision to bring innovative software to patient care,” added Karl Otto, CEO of Limbus AI. “Both companies have very talented and hardworking teams that, when combined, will be able to achieve great things together.”